Meropenem Qilu

Meropenem, the active ingredient in Meropenem Qilu, is a carbapenem antibiotic presented as an injectable powder for reconstitution for intravenous use. It is employed to treat serious bacterial infections in hospitalized patients, including intra‑abdominal, urinary, respiratory, central nervous system and bloodstream infections.

GNH USA supplies Meropenem Qilu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem used for severe bacterial infections affecting various organ systems.

- Complicated intra‑abdominal infections: achieves bacterial eradication and clinical cure. - Complicated urinary tract infections: eliminates pathogenic organisms and resolves infection. - Nosocomial pneumonia: provides effective coverage against resistant respiratory pathogens. - Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis. - Septicemia: rapidly reduces bacteremia and improves survival outcomes.

Adverse reactions may occur with meropenem therapy and are categorized by frequency.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Vomiting: occasional emesis during infusion. - Headache: transient cranial discomfort. - Rash: mild skin erythema or pruritus. - Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects: - Seizures: risk increased in patients with CNS disorders or renal impairment. - Clostridioides difficile infection: possible severe colitis. - Anaphylaxis: acute hypersensitivity reaction requiring immediate intervention. - Renal toxicity: acute kidney injury in susceptible individuals. - Severe hypersensitivity: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hematologic abnormalities: neutropenia or thrombocytopenia.

When using meropenem, clinicians should consider several safety measures.

- Renal function monitoring: adjust dose in patients with impaired clearance. - CNS disorders: use cautiously in patients with seizure history. - Hypersensitivity: avoid in individuals with known carbapenem allergy. - Pregnancy and lactation: assess risk‑benefit as safety data are limited. - Superinfection: monitor for secondary infections such as C. difficile. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with other medicines, requiring attention to the interaction strength.

Major Interactions (Avoid): - Valproic acid: carbapenems reduce serum valproate levels, increasing seizure risk. - Concurrent carbapenems: avoid simultaneous use to prevent additive toxicity. - High‑dose aminoglycosides: increased risk of nephrotoxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: monitor renal function and electrolytes. - NSAIDs: may further impair renal clearance. - Anticoagulants (warfarin): observe INR for potential alterations.